The Epidermolysis Bullosa market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Epidermolysis Bullosa pipeline products will significantly revolutionize the Epidermolysis Bullosa market dynamics.

DelveInsight’s “Epidermolysis Bullosa Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Epidermolysis Bullosa, historical and forecasted epidemiology as well as the Epidermolysis Bullosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Epidermolysis Bullosa market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Epidermolysis Bullosa market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Epidermolysis Bullosa Market Forecast

Some of the key facts of the Epidermolysis Bullosa Market Report:

• The Epidermolysis Bullosa market size was valued at ~USD 1,700 Million in the year 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).

• In September 2025, The FDA approved an update to Vyjuvek (beremagene geperpavec), a gene therapy gel for treating wounds in dystrophic epidermolysis bullosa (DEB) patients, allowing its use in all patients and enabling self-administration at home. Previously approved for DEB patients aged six months and older, the update now extends use to newborns and improves convenience, according to Krystal Biotech, the therapy’s developer.

• In April 2025, Abeona Therapeutics Inc. (Nasdaq: ABEO) has announced that the U.S. Food and Drug Administration (FDA) has approved ZEVASKYN™ (pronounced ‘ZEE-vah-skin’)—prademagene zamikeracel—as the first and only autologous cell-based gene therapy for treating wounds in both adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), a severe and disabling genetic skin disorder. Currently, there is no cure for RDEB, and ZEVASKYN is the only FDA-approved therapy offering wound treatment through a single application.

• In April 2025, DEBRA Research gGmbH, a German non-profit committed to supporting research and drug development for individuals with Epidermolysis Bullosa (EB), is partnering with Viking Global Investors, CureEB, EBMRF, and Stanford University to invest in Nova Anchora LLC. Nova Anchora is an early-stage, preclinical biotechnology company focused on creating innovative protein therapies for EB. This funding will help advance the company’s lead candidate, NvA-011, through preclinical stages and toward IND (Investigational New Drug) readiness.

• In September 2024, In a small real-world study, treatment with Janus kinase (JAK) inhibitors, including upadacitinib and baricitinib, demonstrated greater effectiveness than dupilumab in alleviating itching and skin lesions in individuals with epidermolysis bullosa pruriginosa (EBP). Among five patients on dupilumab, only two achieved a 50% reduction in itching, with none experiencing total relief. In comparison, all five patients treated with JAK inhibitors who had measurable itch scores reported complete relief from itching.

• In 2023, the Epidermolysis Bullosa market size in the US, among the seven major markets (7MM), reached approximately USD 1,300 million, marking the highest figure. It is projected to undergo further growth by 2034.

• In 2023, the United States had the highest prevalence of Epidermolysis Bullosa cases, making up approximately 65% of the total cases among the seven major markets (7MM). Meanwhile, the EU4 countries and the UK comprised around 30%, and Japan accounted for approximately 5% of the total population share in the same year.

• As per DelveInsight’s projections, approximately 18,000 cases of Epidermolysis Bullosa simplex, 1,450 cases of junctional Epidermolysis Bullosa, and 8,500 cases of dystrophic Epidermolysis Bullosa were reported in the United States in 2023.

• Key Epidermolysis Bullosa Companies: Berg Pharma, Holostem Terapie Avanzate, Aegle Therapeutics, RegeneRx Biopharmaceuticals, BridgeBio Pharma, InMed Pharmaceuticals, Fibrocell Science, Krystal Biotech, and others

• Key Epidermolysis Bullosa Therapies: BPM31510, HOLOGENE-17,AGLE102, RGN-137, PTR-01, INM-755, Dabocemagene autoficel, VYJUVEK, and others

Epidermolysis Bullosa Overview

Epidermolysis Bullosa is a group of rare genetic disorders characterized by fragile skin that blisters and forms painful sores in response to minor friction or trauma. This condition is caused by mutations in genes responsible for producing proteins that help anchor the layers of the skin together.

Get a Free sample for the Epidermolysis Bullosa Market Report:

https://www.delveinsight.com/report-store/epidermolysis-bullosa-market

Epidermolysis Bullosa Market

The dynamics of the Epidermolysis Bullosa market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.

“In June 2022, the European Commission (EC) approved FILSUVEZ for the treatment of partial-thickness wounds associated with dystrophic and junctional epidermolysis bullosa in patients six months and older”

Epidermolysis Bullosa Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Epidermolysis Bullosa Epidemiology Segmentation:

The Epidermolysis Bullosa market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Epidermolysis Bullosa

• Prevalent Cases of Epidermolysis Bullosa by severity

• Gender-specific Prevalence of Epidermolysis Bullosa

• Diagnosed Cases of Episodic and Chronic Epidermolysis Bullosa

Download the report to understand which factors are driving Epidermolysis Bullosa epidemiology trends @ Epidermolysis Bullosa Epidemiological Insights

Epidermolysis Bullosa Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Epidermolysis Bullosa market or expected to get launched during the study period. The analysis covers Epidermolysis Bullosa market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Epidermolysis Bullosa Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Epidermolysis Bullosa Therapies and Key Companies

• BPM31510: Berg Pharma

• HOLOGENE-17: Holostem Terapie Avanzate

• AGLE102: Aegle Therapeutics

• RGN-137: RegeneRx Biopharmaceuticals

• PTR-01: BridgeBio Pharma

• INM-755: InMed Pharmaceuticals

• Dabocemagene autoficel: Fibrocell Science

• VYJUVEK: Krystal Biotech

To know more about Epidermolysis Bullosa treatment, visit @ Epidermolysis Bullosa Medications

Epidermolysis Bullosa Market Drivers

• The rise in the prevalence of epidermolysis bullosa

• Robust clinical pipeline containing emerging drugs with novel RoA and MoA

• Gene and cell therapies are also in the clinical stages of development for the treatment of epidermolysis bullosa

• Increase funding support from organizations such as epidermolysis bullosa Research Partnership

Epidermolysis Bullosa Market Unmet Needs

• Challenges in diagnosis

• Lack of effective treatment

• Challenges in the clinical trial

• Poor disease understanding

Scope of the Epidermolysis Bullosa Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Epidermolysis Bullosa Companies: Berg Pharma, Holostem Terapie Avanzate, Aegle Therapeutics, RegeneRx Biopharmaceuticals, BridgeBio Pharma, InMed Pharmaceuticals, Fibrocell Science, Krystal Biotech, and others

• Key Epidermolysis Bullosa Therapies: BPM31510, HOLOGENE-17,AGLE102, RGN-137, PTR-01, INM-755, Dabocemagene autoficel, VYJUVEK, and others

• Epidermolysis Bullosa Therapeutic Assessment: Epidermolysis Bullosa current marketed and Epidermolysis Bullosa emerging therapies

• Epidermolysis Bullosa Market Dynamics: Epidermolysis Bullosa market drivers and Epidermolysis Bullosa market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Epidermolysis Bullosa Unmet Needs, KOL’s views, Analyst’s views, Epidermolysis Bullosa Market Access and Reimbursement

Discover more about therapies set to grab major Epidermolysis Bullosa market share @ Epidermolysis Bullosa Treatment Landscape

Table of Contents

1. Epidermolysis Bullosa Market Report Introduction

2. Executive Summary for Epidermolysis Bullosa

3. SWOT analysis of Epidermolysis Bullosa

4. Epidermolysis Bullosa Patient Share (%) Overview at a Glance

5. Epidermolysis Bullosa Market Overview at a Glance

6. Epidermolysis Bullosa Disease Background and Overview

7. Epidermolysis Bullosa Epidemiology and Patient Population

8. Country-Specific Patient Population of Epidermolysis Bullosa

9. Epidermolysis Bullosa Current Treatment and Medical Practices

10. Epidermolysis Bullosa Unmet Needs

11. Epidermolysis Bullosa Emerging Therapies

12. Epidermolysis Bullosa Market Outlook

13. Country-Wise Epidermolysis Bullosa Market Analysis (2020–2034)

14. Epidermolysis Bullosa Market Access and Reimbursement of Therapies

15. Epidermolysis Bullosa Market Drivers

16. Epidermolysis Bullosa Market Barriers

17. Epidermolysis Bullosa Appendix

18. Epidermolysis Bullosa Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/